Original price was: ₹1,200.00.₹799.00Current price is: ₹799.00.
CA 19-9 (Carbohydrate Antigen 19-9) is a tumor marker primarily associated with pancreatic cancer, but it can also be elevated in other gastrointestinal (GI) cancers and some benign conditions. It is widely used for monitoring disease progression and treatment response rather than for early cancer screening.
| Reference Range | Interpretation |
|---|---|
| < 37 U/mL | Normal |
| > 37 U/mL | Elevated, requires further evaluation |
| > 100 U/mL | High suspicion of malignancy, especially pancreatic cancer |
| > 1,000 U/mL | Often indicates advanced disease or metastasis |
🔹 Very high levels (>10,000 U/mL) strongly suggest widespread cancer, often with liver metastases.
| Condition | Explanation |
|---|---|
| Pancreatic Cancer | Most common cancer associated with CA 19-9 (> 80% cases) |
| Cholangiocarcinoma (Bile Duct Cancer) | Often elevated, used along with imaging |
| Colorectal & Gastric Cancer | Sometimes increased, but not as specific |
| Liver Cirrhosis & Hepatitis | Mild elevations due to bile duct inflammation |
| Benign Pancreatic & Biliary Diseases | Pancreatitis, gallstones, cholestasis, bile duct obstruction can cause elevation |
🔹 Best used in combination with other markers:
Pancreatic cancer → CA 19-9 + CEA
Cholangiocarcinoma (bile duct cancer) → CA 19-9 + AFP
✅ Monitoring Pancreatic Cancer Progression & Treatment Response
✅ Assessing Cancer Recurrence After Surgery or Chemotherapy
✅ Differentiating Pancreatic Cancer from Benign Conditions (when combined with imaging)
🔹 Not useful for early cancer screening – Many early-stage cancers do not raise CA 19-9 levels.
🔹 False positives in benign diseases – Pancreatitis, bile duct obstruction, and cirrhosis can cause mild elevations.
🔹 5–10% of people cannot produce CA 19-9 due to the Lewis antigen-negative blood type, making it unreliable in those individuals.
| CA 19-9 Level | Possible Interpretation |
|---|---|
| < 37 U/mL | Normal, unlikely cancer |
| 37 – 100 U/mL | Possible benign disease or early cancer |
| 100 – 1,000 U/mL | High suspicion of malignancy |
| > 1,000 U/mL | Likely advanced pancreatic cancer or metastasis |
🔹 If CA 19-9 is elevated, imaging (CT, MRI, PET scan) is needed for confirmation.
✅ CA 19-9 is the most important marker for pancreatic cancer but not for early detection.
✅ Best used for monitoring treatment response and detecting recurrence.
✅ Levels > 100 U/mL strongly suggest malignancy, but imaging is required for confirmation.
✅ Can be falsely elevated in benign conditions like pancreatitis, bile duct obstruction, and cirrhosis.
✅ Not useful in Lewis antigen-negative individuals (~5% of the population).